Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122382 · ClinicalTrials.gov registry record · Phase 3
Remission and Joint Damage Progression in Early Rheumatoid Arthritis
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,052
- Enrollment target
NCT00122382: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT00122382 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,052 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00122382, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,052 participants
- Enrollment target
Study Summary
This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
Primary Outcome
Number of participants who achieved remission at Month 12 of treatment, as defined by a Disease Activity Score (DAS) 28-CRP score of \<2.6. DAS 28-CRP is a continuous measure, a composite of 4 variables: number of tender joints out of 28 joints, number of swollen joints out of 28 joints, CRP (in mg/L), and subject assessment of disease activity measure on a Visual Analogue Scale (VAS) of 100 millimeters (mm). The DAS28 scale=0 (best) to 10 (worst), indicating the current activity of the rheumato
Interventions
- DRUG placebo
- DRUG Abatacept
- DRUG methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,052 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
What the finished NCT00122382 record still lists
NCT00122382 is an interventional study that assigns participants to a tested intervention. Its 1,052 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (36% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00122382 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00122382 about?
NCT00122382 is a clinical study titled "Remission and Joint Damage Progression in Early Rheumatoid Arthritis". This is a world wide study to evaluate the remission and joint damage in subjects treated with abatacept in addition to methotrexate versus subjects who receive methotrexate along with a placebo.
What is the current status of trial NCT00122382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,052 participants. The study started on 2005-07. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00122382?
The interventions under investigation include: placebo (DRUG), Abatacept (DRUG), methotrexate (DRUG).
Who is sponsoring clinical trial NCT00122382?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00122382's enrollment target sits among peer trials
1,052 278th of 2000 higher than 1,720 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
- NCT05915377 · 1,050 participants · NA
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia